CTLT - Catalent, Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 55.92

Open

$ 55.87

Bid

$ 55.94 x 100

Ask

$ 0.00 x 0

Day's Range

$ 55.79 - $ 56.10

52 Week Range

$ 31.45 - $ 60.20

Volume

2,846,393

Average Volume

Market Cap

10.11B

Beta (5Y Monthly)

$ 1.27

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-14-2024	12-31-2023	10-Q
2	12-08-2023	06-30-2023	10-K
3	12-08-2023	09-30-2023	10-Q
4	06-12-2023	03-31-2023	10-Q
5	02-07-2023	12-31-2022	10-Q
6	11-01-2022	09-30-2022	10-Q
7	08-29-2022	06-30-2022	10-K
8	05-03-2022	03-31-2022	10-Q
9	02-01-2022	12-31-2021	10-Q
10	11-02-2021	09-30-2021	10-Q
11	08-30-2021	06-30-2021	10-K
12	05-04-2021	03-31-2021	10-Q
13	02-02-2021	12-31-2020	10-Q
14	11-03-2020	09-30-2020	10-Q
15	08-31-2020	06-30-2020	10-K
16	05-05-2020	03-31-2020	10-Q
17	02-03-2020	12-31-2019	10-Q
18	11-05-2019	09-30-2019	10-Q
19	08-27-2019	06-30-2019	10-K
20	05-07-2019	03-31-2019	10-Q
21	02-05-2019	12-31-2018	10-Q
22	11-06-2018	09-30-2018	10-Q
23	08-28-2018	06-30-2018	10-K
24	05-01-2018	03-31-2018	10-Q
25	02-05-2018	12-31-2017	10-Q
26	11-06-2017	09-30-2017	10-Q
27	08-28-2017	06-30-2017	10-K
28	05-04-2017	03-31-2017	10-Q
29	02-06-2017	12-31-2016	10-Q
30	11-07-2016	09-30-2016	10-Q
31	08-29-2016	06-30-2016	10-K
32	05-04-2016	03-31-2016	10-Q
33	02-09-2016	12-31-2015	10-Q
34	11-03-2015	09-30-2015	10-Q
35	09-02-2015	06-30-2015	10-K
36	05-05-2015	03-31-2015	10-Q
37	02-12-2015	12-31-2014	10-Q
38	11-14-2014	09-30-2014	10-Q
39	09-08-2014	06-30-2014	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

novo-nordisks-dominance-in-obesity--diabetes-drug-market-backed-by-strong-pipeline-analyst-gives-outperform-rating

Novo Nordisk's Dominance In Obesity & Diab...
04/12/2024 17:22:39

BMO's coverage of Novo Nordisk, spotlighting its groundbreaking advancements in weight loss and diabetes drugs. Analysts fo...

Beyond The Numbers: 6 Analysts Discuss Cat...
04/04/2024 15:01:07

Stephens & Co. Reiterates Equal-Weight on ...
04/04/2024 14:26:35

Stephens & Co. analyst Jacob Johnson reiterates Catalent (NYSE:CTLT) with a Equal-Weight and maintains $63.5 price target.

Invenra To Collaborate With Catalent To Co...
04/02/2024 17:59:04

https://www.businesswire.com/news/home/20240402320363/en/

novo-nordisk-sets-timeframe-for-its-next-gen-experimental-obesity-drug

Novo Nordisk Sets Timeframe For Its Next-G...
03/08/2024 16:12:01

"Novo Nordisk's optimism soars with promising early trial data for amycretin, an experimental weight loss pill. Expect ...

Novo Nordisk CFO Says If Catalent Deal Doe...
03/07/2024 16:01:02

Novo Nordisk CFO Says If Catalent Deal Doe...
03/07/2024 15:47:42

- Conf Call

escalating-demand-for-obesity-drugs-creates-time-sensitive-race-for-eli-lilly-novo-nordisk

Escalating Demand for Obesity Drugs Create...
03/06/2024 14:33:30

Eli Lilly's strategic collaborations with outsourcing partners for Zepbound (tirzepatide) production. Challenges persist as...

record-high-sp-500-propels-spy-etf-to-500-billion-milestone-nvidia-tops-2-trillion-broadcom-surpasses-tesla

Record-High S&P 500 Propels SPY ETF To $50...
03/01/2024 21:05:12

U.S. stock market continues bull run, hitting record highs for S&P 500 and Nasdaq 100. SPY ETF surpasses $500 billion AUM, ...

top-stocks-not-named-nvidia-you-need-to-know-about-in-2024-heres-what-investors-think-about-them-wall-street-vs-reddit

Top Stocks Not Named Nvidia You Need To Kn...
02/29/2024 21:57:48

Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.

(CTLT) - Analyzing Catalent's Short Interest
02/28/2024 17:30:14

eli-lilly-novo-nordisks-strategies-against-new-weight-loss-drug-competitors

Eli Lilly, Novo Nordisk's Strategies Again...
02/26/2024 16:31:35

Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new ob...

In-Depth Examination Of 5 Analyst Recommen...
02/20/2024 19:00:46

RBC Capital Reiterates Sector Perform on C...
02/20/2024 15:28:19

RBC Capital analyst Sean Dodge reiterates Catalent (NYSE:CTLT) with a Sector Perform and maintains $63.5 price target.

Catalent Says During 3 Months Ended Dec 31...
02/14/2024 20:21:28

- Reuters

Catalent Says Upon Termination Of Merger W...
02/14/2024 20:18:26

- Reuters

nearly-half-of-sp-500-stocks-trade-below-50-day-moving-average-which-one-is-the-cheapest

Nearly Half Of S&P 500 Stocks Trade Below ...
02/14/2024 17:49:15

Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielde...

novo-nordisk-eli-lilly-stride-to-boost-supply-shortage-for-newly-found-holy-grail-of-miraculous-weight-loss-drugs

Novo Nordisk, Eli Lilly Stride To Boost Su...
02/12/2024 13:57:45

Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mo...

Catalent Q2 Adjusted EPS $(0.24) May Not B...
02/09/2024 13:04:34

Catalent (NYSE:CTLT) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.02) by 1...

us-stocks-set-to-open-higher-finish-week-stronger-amid-mixed-earnings-analyst-sees-another-leg-up-ahead-of-historically-weak-march

US Stocks Set To Open Higher, Finish Week ...
02/09/2024 12:32:44

The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in ...